Maya Dajee

机构：VA Palo Alto Health Care System, Novartis (United States), Stanford Medicine, Stanford University · ORCID：0009-0006-3105-9699

发表论文 77 篇 · 总被引 2854 次 · h-index 19

代表论文

• Blockade of IL1β and PD1 with Combination Chemotherapy Reduces Systemic Myeloid Suppression in Metastatic Pancreatic Cancer with Heterogeneous Effects in the Tumor (2024 · Cancer Immunology Research · 被引 34)
• Clinical validation of droplet digital PCR assays in detecting BRAFV600-mutant circulating tumour DNA as a prognostic biomarker in patients with resected stage III melanoma receiving adjuvant therapy (COMBI-AD): a biomarker analysis from a double-blind, randomised phase 3 trial (2025 · The Lancet Oncology · 被引 29)
• Crizanlizumab and inclacumab are equally potent inhibitors of cell adhesion in the blood of patients with sickle cell disease (2025 · Blood Red Cells & Iron · 被引 2)
• Clinical validation of droplet digital PCR assays in detecting BRAF$V^{600}$-mutant circulating tumour DNA as a prognostic biomarker in patients with resected stage III melanoma receiving adjuvant therapy (COMBI-AD): a biomarker analysis from a double-blind, randomised phase 3 trial (2025 · Zurich Open Repository and Archive (University of Zurich) · 被引 2)
• CheckMate 592: A phase II exploratory study of biomarkers associated with the efficacy of first-line nivolumab (nivo) plus ipilimumab (ipi) in patients (pts) with stage IV or recurrent NSCLC (2018 · Annals of Oncology · 被引 2)
• Characterization of Two Anti-P-Selectin Monoclonal Antibodies (mAbs): Crizanlizumab Shows Comparable or Stronger Effects Versus Inclacumab across Cell Adhesion Assays in Vitro (2021 · Blood · 被引 1)